Melanoma accounts for more than 60% of deaths associated with skin cancer, making its early detection through dermatological screening essential for improved treatment outcomes. Early detection and successful treatment of melanoma can dramatically increase the 5-year survival rate from 14 to 98%. To support such efforts, comprehensive identification of metabolite patterns capable of describing cancer progression will help support the foundational knowledge necessary to build early detection platforms for intervention prior to metastasis. Using an UPLC-MS, as part of a cell-based, untargeted metabolomics approach, we profiled the metabolomes of WM-226-4 and WM-115 cells. Derived from the metastatic and the primary sites of the same individual, these two cell lines represent a paired melanoma cancer cell line. Progenesis and MetaboAnalyst, platforms dedicated to metabolomics data analysis, were used to establish a panel of differentially expressed metabolites across these two stages of melanoma. In addition, mummichog was used to identify the affected pathways. A total of 12 differentially expressed metabolites including amino acids, carnitine, acylcarnitine, and a limited set of lipids were identified. The significantly differing metabolites are components of a diverse set of metabolic pathways (e.g., glycerophospholipid metabolism, carnitine shuttle, tryptophan metabolism), that have biological implications for the survival and dissemination of metastatic melanoma cells.

黑色素瘤占皮肤癌相关死亡的 60% 以上，因此通过皮肤病学筛查早期发现黑色素瘤对于改善治疗结果至关重要。黑色素瘤的早期发现和成功治疗可以将 5 年生存率从 14% 大幅提高到 98%。为了支持这些努力，全面鉴定能够描述癌症进展的代谢模式将有助于支持建立转移前干预的早期检测平台所需的基础知识。使用 UPLC-MS 作为基于细胞的非靶向代谢组学方法的一部分，我们分析了 WM-226-4 和 WM-115 细胞的代谢组。这两种细胞系源自同一个体的转移部位和原发部位，代表配对的黑色素瘤癌细胞系。 Progenesis 和 MetaboAnalyst 是专门用于代谢组学数据分析的平台，用于建立一组跨越黑色素瘤这两个阶段的差异表达代谢物。此外， mummichog用于识别受影响的途径。总共鉴定出 12 种差异表达的代谢物，包括氨基酸、肉碱、酰基肉碱和有限的脂质。显着不同的代谢物是多种代谢途径（例如甘油磷脂代谢、肉碱穿梭、色氨酸代谢）的组成部分，这些代谢途径对转移性黑色素瘤细胞的存活和扩散具有生物学意义。